Back to top
more

athenahealth, Inc. (ATHN)

(Delayed Data from NSDQ)

$134.99 USD

134.99
NA

0.00 (0.00%)

Updated Feb 11, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Veeva Rolls Out Nitro to Unify Healthcare Industry Data

Veeva (VEEV) strengthens its position by providing the life sciences industry with a streamlined commercial database besides notable technological innovations.

    Ryan McQueeney headshot

    Why Athenahealth (ATHN) Is a Major Medtech Acquisition Target

    On today's episode of the Tech Talk Tuesday podcast, Ryan McQueeney discusses Athenahealth (ATHN), a medical technology company that has found itself the target of an activist takeover from Paul Singer's Elliott Management.

      Ryan McQueeney headshot

      Why Did Athenahealth (ATHN) Stock Soar Today?

      Shares of Athenahealth (ATHN) opened more than 20% higher on Monday after Paul Singer's Elliott Management offered to buy the healthcare technology company in an all-cash deal valued at $160 per share.

        athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q1

        Revenues in Business and Services along with a strong client base boost athenahealth's (ATHN) Q1 earnings.

          Can Business Services Aid athenahealth's (ATHN) Q1 Earnings?

          athenahealth's (ATHN) strong product portfolio, network expansion strategies and unique business model are likely to drive Q1 earnings.

            Haemonetics Rides High on Plasma, Blood Center Remains Weak

            We are optimistic about Haemonetics' (HAE) improved Plasma franchise as strong end-market demand for plasma-derived biopharmaceuticals consistently drives growth for the company.

              GNC Holdings Partners Rapid Nutrition, Forays in Australia

              GNC Holdings' (GNC) tie-up with Rapid Nutrition is likely to fuel the company's entry and expansion into the Australian healthcare market.

                Supply Delay Hits Zimmer Biomet, Operational Plan Buoys Hope

                Zimmer Biomet's (ZBH) dull Knee sales continue to bother due to slower pace of supply recovery and sales recapture of certain key brands.

                  Hill-Rom Banks on Product Innovation, Strategic Buyouts

                  Hill-Rom (HRC) sets sights on product innovation, the latest launch being Connex Cardio ECG. The company also revises its 2020 financial aims and outlook, backed by new tax reform-related benefits.

                    Cerner's EHR to Aid Kern Medical's Population Management

                    Cerner's (CERN) coveted Millennium and HelatheIntent EHR platforms to overhaul Kern Medical's array of services.

                      Medtronic to Grow on Strong Fundamentals, High Costs a Woe

                      Medtronic's (MDT) latest restructuring Enterprise Excellence plan intends to achieve $3 billion of annual growth run rate savings by the end of fiscal 2022

                        Align Unveils Vivera Retainers for Deep Bite Correction

                        Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.

                          Align Technology Broadens Invisalign Suite, Extends Reach

                          Align Technology (ALGN) leaves no stone unturned to boost the Invisalign product portfolio and strengthen its hold in the high-potential invisible orthodontics market.

                            ABIOMED's (ABMD) Impella 5.5 Receives CE Mark in Europe

                            ABIOMED's (ABMD) Impella line consistently boosts earnings in and outside the United States. Its Impella 5.5 successfully treats first patient at University Heart Center, Hamburg.

                              Nabaparna Bhattacharya headshot

                              MedTech Takes to Big Data Analytics: 3 Stocks Catch Eye

                              Here we take a look at the major factors that are driving the importance of big data in the MedTech space.

                                Myriad Genetics' BRACAnalysis Test Platform Gets PMA in Japan

                                Myriad Genetics (MYGN) leaves no stone unturned to boost uptake of BRACAnalysis test and strengthen the Molecular Diagnostics portfolio.

                                  Masimo (MASI) Launches UniView, Improves Patient Safety

                                  Masimo's (MASI) strategy to target hospitals and consumer market is likely to provide it a competitive edge in the U.S. MedTech sector.

                                    Here's Why You Should Invest in ABIOMED (ABMD) Right Now

                                    ABIOMED's (ABMD) flagship Impella holds promise. A raised guidance encourages.

                                      Cooper (COO) Buys LifeGlobal to Widen Fertility Device Line

                                      Cooper Companies' (COO) LifeGlobal asset purchase is likely to boost CooperSurgical.

                                        Here's Why You Should Invest in Surmodics (SRDX) Right Now

                                        Surmodics (SRDX) continues to benefit from solid growth in the In Vitro Diagnostics (IVD) segment.

                                          Boston Scientific to Acquire Securus Medical, Boost EP Unit

                                          Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.

                                            Zacks.com highlights: athenahealth, Applied Materials, Pioneer Natural Resources and TriNet Group

                                            Zacks.com highlights: athenahealth, Applied Materials, Pioneer Natural Resources and TriNet Group

                                              FDA Nod for Abiomed Impella CP with SmartAssist Widens Suite

                                              Abiomed (ABMD) continues with the slew of developments to boost its flagship, Impella product line.

                                                IRCCO Picks Cerner's HealtheIntent for Patients of Illinois

                                                Cerner's (CERN) HealtheIntent intends to serve 20,000 Medicare patients in Illinois through IRCCO's accountable care organizations.

                                                  AngioDynamics (ANGO) Product Line Strong, Debt Level High

                                                  AngioDynamics (ANGO) rides on promising NanoKnife performance. Dwindling sales are a concern.